Vermillion, Inc. VRML shares were trading higher on Wednesday, after the company announced it completed validation of new pre-surgical test offerings with OVA1 plus, including coronavirus antibody testings.
The company is also expected to join the Russell 3000 Index on June 29.
Vermillion is a diagnostic service and bio-analytic solutions provider company. It is engaged in the business of developing and commercializing diagnostic tests for the gynecologic disease. The company's products include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It serves clinical reference laboratories, hospital laboratories, and physician offices. Geographically all the operations are functioned from the region of U.S.
Vermillion shares are trading up 7.13% at $4.81 at time of publication on Wednesday. The stock has a 52-week high of $5.78 and a 52-week low of 35 cents.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
